IDEAS home Printed from https://ideas.repec.org/f/pho785.html
   My authors  Follow this author

Jeffrey Hoch

Personal Details

First Name:Jeffrey
Middle Name:
Last Name:Hoch
Suffix:
RePEc Short-ID:pho785
[This author has chosen not to make the email address public]

Affiliation

Division of Health Policy and Management
Department of Public Health Sciences
School of Medecine
University of California-Davis

Davis, California (United States)
https://health.ucdavis.edu/phs/divisions/hpm/
RePEc:edi:hpucdus (more details at EDIRC)

Research output

as
Jump to: Articles Chapters

Articles

  1. Sandjar Djalalov & Jaclyn Beca & Emmanuel M. Ewara & Jeffrey S. Hoch, 2019. "A Comparison of Different Analysis Methods for Reconstructed Survival Data to Inform Cost‑Effectiveness Analysis," PharmacoEconomics, Springer, vol. 37(12), pages 1525-1536, December.
  2. Jaclyn Beca & Don Husereau & Kelvin K. W. Chan & Neil Hawkins & Jeffrey S. Hoch, 2018. "Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment," PharmacoEconomics, Springer, vol. 36(1), pages 7-15, January.
  3. Malek B. Hannouf & Eric Winquist & Salaheddin M. Mahmud & Muriel Brackstone & Sisira Sarma & George Rodrigues & Peter K. Rogan & Jeffrey S. Hoch & Gregory S. Zaric, 2018. "The Potential Clinical and Economic Value of Primary Tumour Identification in Metastatic Cancer of Unknown Primary Tumour: A Population-Based Retrospective Matched Cohort Study," PharmacoEconomics - Open, Springer, vol. 2(3), pages 255-270, September.
  4. David G. T. Whitehurst & Nicholas R. Latimer & Aura Kagan & Rebecca Palmer & Nina Simmons-Mackie & J. Charles Victor & Jeffrey S. Hoch, 2018. "Developing Accessible, Pictorial Versions of Health-Related Quality-of-Life Instruments Suitable for Economic Evaluation: A Report of Preliminary Studies Conducted in Canada and the United Kingdom," PharmacoEconomics - Open, Springer, vol. 2(3), pages 225-231, September.
  5. Kavisha Jayasundara & Murray Krahn & Muhammad Mamdani & Jeffrey S. Hoch & Paul Grootendorst, 2017. "Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology," PharmacoEconomics - Open, Springer, vol. 1(3), pages 167-173, September.
  6. Lisa Masucci & Jaclyn Beca & Mona Sabharwal & Jeffrey S. Hoch, 2017. "Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR)," PharmacoEconomics - Open, Springer, vol. 1(4), pages 255-263, December.
  7. S Lucas Goede & Linda Rabeneck & Marjolein van Ballegooijen & Ann G Zauber & Lawrence F Paszat & Jeffrey S Hoch & Jean H E Yong & Sonja Kroep & Jill Tinmouth & Iris Lansdorp-Vogelaar, 2017. "Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening," PLOS ONE, Public Library of Science, vol. 12(3), pages 1-15, March.
  8. Carolyn S Dewa & Lucy Trojanowski & Sietske J Tamminga & Jolie Ringash & Maurene McQuestion & Jeffrey S Hoch, 2016. "Advice about Work-Related Issues to Peers and Employers from Head and Neck Cancer Survivors," PLOS ONE, Public Library of Science, vol. 11(4), pages 1-13, April.
  9. Amy Tawfik & Walter P. Wodchis & Petros Pechlivanoglou & Jeffrey Hoch & Don Husereau & Murray Krahn, 2016. "Using Phase-Based Costing of Real-World Data to Inform Decision–Analytic Models for Atrial Fibrillation," Applied Health Economics and Health Policy, Springer, vol. 14(3), pages 313-322, June.
  10. Jeffrey Hoch & Jaclyn Beca & Mona Sabharwal & Scott Livingstone & Anthony Fields, 2015. "Does it Matter Whether Canada’s Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?," PharmacoEconomics, Springer, vol. 33(8), pages 879-882, August.
  11. Wanrudee Isaranuwatchai & Maureen Markle-Reid & Jeffrey Hoch, 2015. "Adjusting for Baseline Covariates in Net Benefit Regression: How You Adjust Matters," PharmacoEconomics, Springer, vol. 33(10), pages 1083-1090, October.
  12. Regier, Dean A. & Bentley, Colene & Mitton, Craig & Bryan, Stirling & Burgess, Michael M. & Chesney, Ellen & Coldman, Andy & Gibson, Jennifer & Hoch, Jeffrey & Rahman, Syed & Sabharwal, Mona & Sawka, , 2014. "Public engagement in priority-setting: Results from a pan-Canadian survey of decision-makers in cancer control," Social Science & Medicine, Elsevier, vol. 122(C), pages 130-139.
  13. Sandjar Djalalov & Linda Rabeneck & George Tomlinson & Karen E. Bremner & Robert Hilsden & Jeffrey S. Hoch, 2014. "A Review and Meta-analysis of Colorectal Cancer Utilities," Medical Decision Making, , vol. 34(6), pages 809-818, August.
  14. Jean Yong & Jaclyn Beca & Jeffrey Hoch, 2013. "The Evaluation and Use of Economic Evidence to Inform Cancer Drug Reimbursement Decisions in Canada," PharmacoEconomics, Springer, vol. 31(3), pages 229-236, March.
  15. Hoch, Jeffrey S. & Blume, Jeffrey D., 2008. "Measuring and illustrating statistical evidence in a cost-effectiveness analysis," Journal of Health Economics, Elsevier, vol. 27(2), pages 476-495, March.
  16. Jeffrey Hoch & Carolyn Dewa, 2007. "Lessons from Trial-Based Cost-Effectiveness Analyses of Mental Health Interventions," PharmacoEconomics, Springer, vol. 25(10), pages 807-816, October.
  17. Andrew R. Willan & Andrew H. Briggs & Jeffrey S. Hoch, 2004. "Regression methods for covariate adjustment and subgroup analysis for non‐censored cost‐effectiveness data," Health Economics, John Wiley & Sons, Ltd., vol. 13(5), pages 461-475, May.
  18. Jeffrey S. Hoch & Andrew H. Briggs & Andrew R. Willan, 2002. "Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost‐effectiveness analysis," Health Economics, John Wiley & Sons, Ltd., vol. 11(5), pages 415-430, July.

Chapters

  1. Carolyn S. Dewa & Jeffrey S. Hoch, 2021. "Labs and cases in health insurance and cost-effectiveness analyses to enhance active learning experiences in an introductory healtheconomics course for students in health professions," Chapters, in: Maia Platt & Allen C. Goodman (ed.), Handbook on Teaching Health Economics, chapter 4, pages 44-60, Edward Elgar Publishing.
  2. Jeffrey S. Hoch & Carolyn S. Dewa, 2021. "Using net benefit regression to teach cost-effectiveness analysis with a dataset," Chapters, in: Maia Platt & Allen C. Goodman (ed.), Handbook on Teaching Health Economics, chapter 6, pages 77-87, Edward Elgar Publishing.
  3. Jeffrey S. Hoch & Pierre Chaussé, 2018. "Econometric Considerations When Using the Net Benefit Regression Framework to Conduct Cost-effectiveness Analysis," Contributions to Economic Analysis, in: Health Econometrics, volume 127, pages 119-143, Emerald Group Publishing Limited.
  4. Jeffrey S. Hoch, 2013. "Improving the Efficiency of Cost-effectiveness Analysis to Inform Policy Decisions in the Real World: Lessons from the Pharmacoeconomics Research Unit at Cancer Care Ontario," International Series in Operations Research & Management Science, in: Gregory S. Zaric (ed.), Operations Research and Health Care Policy, edition 127, chapter 0, pages 399-416, Springer.

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Blog mentions

As found by EconAcademics.org, the blog aggregator for Economics research:
  1. Jaclyn Beca & Don Husereau & Kelvin K. W. Chan & Neil Hawkins & Jeffrey S. Hoch, 2018. "Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment," PharmacoEconomics, Springer, vol. 36(1), pages 7-15, January.

    Mentioned in:

    1. Don Husereau’s journal round-up for 25th November 2019
      by Don Husereau in The Academic Health Economists' Blog on 2019-11-25 12:00:55

Articles

  1. S Lucas Goede & Linda Rabeneck & Marjolein van Ballegooijen & Ann G Zauber & Lawrence F Paszat & Jeffrey S Hoch & Jean H E Yong & Sonja Kroep & Jill Tinmouth & Iris Lansdorp-Vogelaar, 2017. "Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening," PLOS ONE, Public Library of Science, vol. 12(3), pages 1-15, March.

    Cited by:

    1. Joan Mendivil & Marilena Appierto & Susana Aceituno & Mercè Comas & Montserrat Rué, 2019. "Economic evaluations of screening strategies for the early detection of colorectal cancer in the average-risk population: A systematic literature review," PLOS ONE, Public Library of Science, vol. 14(12), pages 1-18, December.

  2. Carolyn S Dewa & Lucy Trojanowski & Sietske J Tamminga & Jolie Ringash & Maurene McQuestion & Jeffrey S Hoch, 2016. "Advice about Work-Related Issues to Peers and Employers from Head and Neck Cancer Survivors," PLOS ONE, Public Library of Science, vol. 11(4), pages 1-13, April.

    Cited by:

    1. Su-Erh Chiu & Kuei-An Cho & Bing-Shen Huang & Chien-Yu Lin & Ching-Fang Chung & Ya-Lan Chang & Shu-Ching Chen, 2023. "Factors Facilitating or Creating Barriers to Returning to Work in Head and Neck Cancer Patients Within the First 6 Months After Treatment," Clinical Nursing Research, , vol. 32(1), pages 197-208, January.

  3. Wanrudee Isaranuwatchai & Maureen Markle-Reid & Jeffrey Hoch, 2015. "Adjusting for Baseline Covariates in Net Benefit Regression: How You Adjust Matters," PharmacoEconomics, Springer, vol. 33(10), pages 1083-1090, October.

    Cited by:

    1. Mohamed El Alili & Johanna M. van Dongen & Jonas L. Esser & Martijn W. Heymans & Maurits W. van Tulder & Judith E. Bosmans, 2022. "A scoping review of statistical methods for trial‐based economic evaluations: The current state of play," Health Economics, John Wiley & Sons, Ltd., vol. 31(12), pages 2680-2699, December.

  4. Regier, Dean A. & Bentley, Colene & Mitton, Craig & Bryan, Stirling & Burgess, Michael M. & Chesney, Ellen & Coldman, Andy & Gibson, Jennifer & Hoch, Jeffrey & Rahman, Syed & Sabharwal, Mona & Sawka, , 2014. "Public engagement in priority-setting: Results from a pan-Canadian survey of decision-makers in cancer control," Social Science & Medicine, Elsevier, vol. 122(C), pages 130-139.

    Cited by:

    1. Rooshenas, Leila & Owen-Smith, Amanda & Hollingworth, William & Badrinath, Padmanabhan & Beynon, Claire & Donovan, Jenny L., 2015. "“I won't call it rationing…”: An ethnographic study of healthcare disinvestment in theory and practice," Social Science & Medicine, Elsevier, vol. 128(C), pages 273-281.
    2. Boxebeld, Sander & Geijsen, Tom & Tuit, Charlotte & Exel, Job van & Makady, Amr & Maes, Laurence & van Agthoven, Michel & Mouter, Niek, 2024. "Public preferences for the allocation of societal resources over different healthcare purposes," Social Science & Medicine, Elsevier, vol. 341(C).

  5. Sandjar Djalalov & Linda Rabeneck & George Tomlinson & Karen E. Bremner & Robert Hilsden & Jeffrey S. Hoch, 2014. "A Review and Meta-analysis of Colorectal Cancer Utilities," Medical Decision Making, , vol. 34(6), pages 809-818, August.

    Cited by:

    1. S Lucas Goede & Linda Rabeneck & Marjolein van Ballegooijen & Ann G Zauber & Lawrence F Paszat & Jeffrey S Hoch & Jean H E Yong & Sonja Kroep & Jill Tinmouth & Iris Lansdorp-Vogelaar, 2017. "Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening," PLOS ONE, Public Library of Science, vol. 12(3), pages 1-15, March.
    2. James Kingsley & Siddharth Karanth & Frances Lee Revere & Deepak Agrawal, 2016. "Cost Effectiveness of Screening Colonoscopy Depends on Adequate Bowel Preparation Rates – A Modeling Study," PLOS ONE, Public Library of Science, vol. 11(12), pages 1-17, December.
    3. Michael J. Zoratti & A. Simon Pickard & Peep F. M. Stalmeier & Daniel Ollendorf & Andrew Lloyd & Kelvin K W Chan & Don Husereau & John E. Brazier & Murray Krahn & Mitchell Levine & Lehana Thabane & Fe, 2021. "Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(5), pages 723-733, July.
    4. Jiryoun Gong & Juhee Han & Donghwan Lee & Seungjin Bae, 2020. "A Meta-Regression Analysis of Utility Weights for Breast Cancer: The Power of Patients’ Experience," IJERPH, MDPI, vol. 17(24), pages 1-16, December.
    5. Tristan M Snowsill & Neil A J Ryan & Emma J Crosbie & Ian M Frayling & D Gareth Evans & Chris J Hyde, 2019. "Cost-effectiveness analysis of reflex testing for Lynch syndrome in women with endometrial cancer in the UK setting," PLOS ONE, Public Library of Science, vol. 14(8), pages 1-18, August.

  6. Jean Yong & Jaclyn Beca & Jeffrey Hoch, 2013. "The Evaluation and Use of Economic Evidence to Inform Cancer Drug Reimbursement Decisions in Canada," PharmacoEconomics, Springer, vol. 31(3), pages 229-236, March.

    Cited by:

    1. Steven Simoens, 2013. "Assessment of Methodological Quality of Economic Evaluations in Belgian Drug Reimbursement Applications," PLOS ONE, Public Library of Science, vol. 8(12), pages 1-1, December.
    2. W. Dominika Wranik & Liesl Gambold & Natasha Hanson & Adrian Levy, 2017. "The evolution of the cancer formulary review in Canada: Can centralization improve the use of economic evaluation?," International Journal of Health Planning and Management, Wiley Blackwell, vol. 32(2), pages 232-260, April.
    3. Eun-Young Bae & Hui Jeong Kim & Hye-Jae Lee & Junho Jang & Seung Min Lee & Yunkyung Jung & Nari Yoon & Tae Kyung Kim & Kookhee Kim & Bong-Min Yang, 2018. "Role of economic evidence in coverage decision-making in South Korea," PLOS ONE, Public Library of Science, vol. 13(10), pages 1-12, October.

  7. Hoch, Jeffrey S. & Blume, Jeffrey D., 2008. "Measuring and illustrating statistical evidence in a cost-effectiveness analysis," Journal of Health Economics, Elsevier, vol. 27(2), pages 476-495, March.

    Cited by:

    1. Dirk Müller & Eleanor Pullenayegum & Afschin Gandjour, 2015. "Impact of small study bias on cost-effectiveness acceptability curves and value of information analyses," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(2), pages 219-223, March.
    2. Sennen Hounton & David Newlands, 2012. "Applying the Net-Benefit Framework for Analyzing and Presenting Cost-Effectiveness Analysis of a Maternal and Newborn Health Intervention," PLOS ONE, Public Library of Science, vol. 7(7), pages 1-8, July.
    3. David R. Bickel, 2021. "The sufficiency of the evidence, the relevancy of the evidence, and quantifying both with a single number," Statistical Methods & Applications, Springer;Società Italiana di Statistica, vol. 30(4), pages 1157-1174, October.

  8. Jeffrey Hoch & Carolyn Dewa, 2007. "Lessons from Trial-Based Cost-Effectiveness Analyses of Mental Health Interventions," PharmacoEconomics, Springer, vol. 25(10), pages 807-816, October.

    Cited by:

    1. Nikki McCaffrey & Meera Agar & Janeane Harlum & Jonathon Karnon & David Currow & Simon Eckermann, 2015. "Better Informing Decision Making with Multiple Outcomes Cost-Effectiveness Analysis under Uncertainty in Cost-Disutility Space," PLOS ONE, Public Library of Science, vol. 10(3), pages 1-19, March.
    2. Sennen Hounton & David Newlands, 2012. "Applying the Net-Benefit Framework for Analyzing and Presenting Cost-Effectiveness Analysis of a Maternal and Newborn Health Intervention," PLOS ONE, Public Library of Science, vol. 7(7), pages 1-8, July.
    3. Hoch, Jeffrey S. & Blume, Jeffrey D., 2008. "Measuring and illustrating statistical evidence in a cost-effectiveness analysis," Journal of Health Economics, Elsevier, vol. 27(2), pages 476-495, March.

  9. Andrew R. Willan & Andrew H. Briggs & Jeffrey S. Hoch, 2004. "Regression methods for covariate adjustment and subgroup analysis for non‐censored cost‐effectiveness data," Health Economics, John Wiley & Sons, Ltd., vol. 13(5), pages 461-475, May.

    Cited by:

    1. Noémi Kreif & Richard Grieve & M. Zia Sadique, 2013. "Statistical Methods For Cost‐Effectiveness Analyses That Use Observational Data: A Critical Appraisal Tool And Review Of Current Practice," Health Economics, John Wiley & Sons, Ltd., vol. 22(4), pages 486-500, April.
    2. Qi Cao & Erik Buskens & Hans L. Hillege & Tiny Jaarsma & Maarten Postma & Douwe Postmus, 2019. "Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(3), pages 475-482, April.
    3. Abualbishr Alshreef & Allan J. Wailoo & Steven R. Brown & James P. Tiernan & Angus J. M. Watson & Katie Biggs & Mike Bradburn & Daniel Hind, 2017. "Cost-Effectiveness of Haemorrhoidal Artery Ligation versus Rubber Band Ligation for the Treatment of Grade II–III Haemorrhoids: Analysis Using Evidence from the HubBLe Trial," PharmacoEconomics - Open, Springer, vol. 1(3), pages 175-184, September.
    4. Daisuke Goto & Ya-Chen Tina Shih & Pascal Lecomte & Melvin Olson & Chukwukadibia Udeze & Yujin Park & C. Daniel Mullins, 2017. "Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 35(7), pages 685-695, July.
    5. Karolien E M Biesheuvel-Leliefeld & Judith E Bosmans & Sandra M A Dijkstra-Kersten & Filip Smit & Claudi L H Bockting & Digna J F van Schaik & Harm W J van Marwijk & Henriette E van der Horst, 2018. "A supported self-help for recurrent depression in primary care; An economic evaluation alongside a multi-center randomised controlled trial," PLOS ONE, Public Library of Science, vol. 13(12), pages 1-18, December.
    6. Carmen Selva-Sevilla & Elena Conde-Montero & Manuel Gerónimo-Pardo, 2020. "Bayesian Regression Model for a Cost-Utility and Cost-Effectiveness Analysis Comparing Punch Grafting Versus Usual Care for the Treatment of Chronic Wounds," IJERPH, MDPI, vol. 17(11), pages 1-21, May.
    7. Jasjeet Singh Sekhon & Richard D. Grieve, 2012. "A matching method for improving covariate balance in cost‐effectiveness analyses," Health Economics, John Wiley & Sons, Ltd., vol. 21(6), pages 695-714, June.
    8. Sabrina Storgaard Sørensen & Kjeld Møller Pedersen & Ulla Møller Weinreich & Lars Ehlers, 2017. "Economic Evaluation of Community-Based Case Management of Patients Suffering From Chronic Obstructive Pulmonary Disease," Applied Health Economics and Health Policy, Springer, vol. 15(3), pages 413-424, June.
    9. Kifmann, Mathias & Siciliani, Luigi, 2014. "Average-cost pricing and dynamic selection incentives in the hospital sector," hche Research Papers 8, University of Hamburg, Hamburg Center for Health Economics (hche).
    10. Nicholas Illenberger & Nandita Mitra & Andrew J. Spieker, 2022. "A regression framework for a probabilistic measure of cost‐effectiveness," Health Economics, John Wiley & Sons, Ltd., vol. 31(7), pages 1438-1451, July.
    11. Andrea Manca & Neil Hawkins & Mark J. Sculpher, 2005. "Estimating mean QALYs in trial‐based cost‐effectiveness analysis: the importance of controlling for baseline utility," Health Economics, John Wiley & Sons, Ltd., vol. 14(5), pages 487-496, May.
    12. Rachael Hunter & Gianluca Baio & Thomas Butt & Stephen Morris & Jeff Round & Nick Freemantle, 2015. "An Educational Review of the Statistical Issues in Analysing Utility Data for Cost-Utility Analysis," PharmacoEconomics, Springer, vol. 33(4), pages 355-366, April.
    13. Manuel Gomes & Richard Grieve & Richard Nixon & W. J. Edmunds, 2012. "Statistical Methods for Cost-Effectiveness Analyses That Use Data from Cluster Randomized Trials," Medical Decision Making, , vol. 32(1), pages 209-220, January.
    14. Moreno, E. & Girón, F.J. & Martínez, M.L. & Vázquez-Polo, F.J. & Negrín, M.A., 2013. "Optimal treatments in cost-effectiveness analysis in the presence of covariates: Improving patient subgroup definition," European Journal of Operational Research, Elsevier, vol. 226(1), pages 173-182.
    15. Moreno, Elías & Girón, F.J. & Vázquez-Polo, F.J. & Negrín, M.A., 2012. "Optimal healthcare decisions: The importance of the covariates in cost–effectiveness analysis," European Journal of Operational Research, Elsevier, vol. 218(2), pages 512-522.
    16. Jeffrey Hoch & Carolyn Dewa, 2007. "Lessons from Trial-Based Cost-Effectiveness Analyses of Mental Health Interventions," PharmacoEconomics, Springer, vol. 25(10), pages 807-816, October.
    17. Andrew Briggs, 2012. "Statistical Methods for Cost-effectiveness Analysis Alongside Clinical Trials," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 50, Edward Elgar Publishing.
    18. John Hutton, 2012. "‘Health Economics’ and the evolution of economic evaluation of health technologies," Health Economics, John Wiley & Sons, Ltd., vol. 21(1), pages 13-18, January.
    19. Richard Grieve & Richard Nixon & Simon G. Thompson & John Cairns, 2007. "Multilevel models for estimating incremental net benefits in multinational studies," Health Economics, John Wiley & Sons, Ltd., vol. 16(8), pages 815-826, August.
    20. Matthew Franklin & James Lomas & Simon Walker & Tracey Young, 2019. "An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 37(5), pages 631-643, May.
    21. Mohamed El Alili & Johanna M. van Dongen & Jonas L. Esser & Martijn W. Heymans & Maurits W. van Tulder & Judith E. Bosmans, 2022. "A scoping review of statistical methods for trial‐based economic evaluations: The current state of play," Health Economics, John Wiley & Sons, Ltd., vol. 31(12), pages 2680-2699, December.
    22. Kelvin K. W. Chan & Feng Xie & Andrew R. Willan & Eleanor M. Pullenayegum, 2018. "Conducting EQ-5D Valuation Studies in Resource-Constrained Countries: The Potential Use of Shrinkage Estimators to Reduce Sample Size," Medical Decision Making, , vol. 38(1), pages 26-33, January.
    23. Andrea Manca & Paul C. Lambert & Mark Sculpher & Nigel Rice, 2007. "Cost-Effectiveness Analysis Using Data from Multinational Trials: The Use of Bivariate Hierarchical Modeling," Medical Decision Making, , vol. 27(4), pages 471-490, July.
    24. Negri­n, Miguel A. & Vázquez-Polo, Francisco-José, 2008. "Incorporating model uncertainty in cost-effectiveness analysis: A Bayesian model averaging approach," Journal of Health Economics, Elsevier, vol. 27(5), pages 1250-1259, September.
    25. Theodoros Mantopoulos & Paul M. Mitchell & Nicky J. Welton & Richard McManus & Lazaros Andronis, 2016. "Choice of statistical model for cost-effectiveness analysis and covariate adjustment: empirical application of prominent models and assessment of their results," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(8), pages 927-938, November.
    26. Yu-Wen Wen & Yi-Wen Tsai & David Bin-Chia Wu & Pei-Fen Chen, 2013. "The Impact of Outliers on Net-Benefit Regression Model in Cost-Effectiveness Analysis," PLOS ONE, Public Library of Science, vol. 8(6), pages 1-9, June.
    27. Gomes, M & Grieve, R, 2011. "Estimating the Effects of Friendship Networks on Health Behaviors of Adolescents," Health, Econometrics and Data Group (HEDG) Working Papers 11/14, HEDG, c/o Department of Economics, University of York.
    28. Hanna Waart & Johanna M. Dongen & Wim H. Harten & Martijn M. Stuiver & Rosalie Huijsmans & Jeannette A. J. H. Hellendoorn-van Vreeswijk & Gabe S. Sonke & Neil K. Aaronson, 2018. "Cost–utility and cost-effectiveness of physical exercise during adjuvant chemotherapy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(6), pages 893-904, July.
    29. Rita Faria & Manuel Gomes & David Epstein & Ian White, 2014. "A Guide to Handling Missing Data in Cost-Effectiveness Analysis Conducted Within Randomised Controlled Trials," PharmacoEconomics, Springer, vol. 32(12), pages 1157-1170, December.
    30. Francisco-José Polo & Miguel Negrín & Xavier Badía & Montse Roset, 2005. "Bayesian regression models for cost-effectiveness analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(1), pages 45-52, March.
    31. Carmen Selva-Sevilla & F Dámaso Fernández-Ginés & Manuel Cortiñas-Sáenz & Manuel Gerónimo-Pardo, 2021. "Cost-effectiveness analysis of domiciliary topical sevoflurane for painful leg ulcers," PLOS ONE, Public Library of Science, vol. 16(9), pages 1-18, September.
    32. Richard M. Nixon & David Wonderling & Richard D. Grieve, 2010. "Non‐parametric methods for cost‐effectiveness analysis: the central limit theorem and the bootstrap compared," Health Economics, John Wiley & Sons, Ltd., vol. 19(3), pages 316-333, March.
    33. Manuel Gomes & Edmond S.-W. Ng & Richard Grieve & Richard Nixon & James Carpenter & Simon G. Thompson, 2012. "Developing Appropriate Methods for Cost-Effectiveness Analysis of Cluster Randomized Trials," Medical Decision Making, , vol. 32(2), pages 350-361, March.
    34. Richard M. Nixon & Simon G. Thompson, 2005. "Methods for incorporating covariate adjustment, subgroup analysis and between‐centre differences into cost‐effectiveness evaluations," Health Economics, John Wiley & Sons, Ltd., vol. 14(12), pages 1217-1229, December.
    35. Becky Pennington & Abualbishr Alshreef & Laura Flight & Andrew Metry & Edith Poku & Philip Hykin & Sobha Sivaprasad & A. Toby Prevost & Joana C. Vasconcelos & Caroline Murphy & Joanna Kelly & Yit Yang, 2021. "Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study," PharmacoEconomics, Springer, vol. 39(8), pages 913-927, August.
    36. Casey Quinn, 2005. "Generalisable regression methods for costeffectiveness using copulas," Health, Econometrics and Data Group (HEDG) Working Papers 05/13, HEDG, c/o Department of Economics, University of York.

  10. Jeffrey S. Hoch & Andrew H. Briggs & Andrew R. Willan, 2002. "Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost‐effectiveness analysis," Health Economics, John Wiley & Sons, Ltd., vol. 11(5), pages 415-430, July.

    Cited by:

    1. Andrea Manca & Nigel Rice & Mark J. Sculpher & Andrew H. Briggs, 2005. "Assessing generalisability by location in trial‐based cost‐effectiveness analysis: the use of multilevel models," Health Economics, John Wiley & Sons, Ltd., vol. 14(5), pages 471-485, May.
    2. Noemi Kreif & Richard Grieve & Rosalba Radice & Zia Sadique & Roland Ramsahai & Jasjeet S. Sekhon, 2012. "Methods for Estimating Subgroup Effects in Cost-Effectiveness Analyses That Use Observational Data," Medical Decision Making, , vol. 32(6), pages 750-763, November.
    3. Noémi Kreif & Richard Grieve & M. Zia Sadique, 2013. "Statistical Methods For Cost‐Effectiveness Analyses That Use Observational Data: A Critical Appraisal Tool And Review Of Current Practice," Health Economics, John Wiley & Sons, Ltd., vol. 22(4), pages 486-500, April.
    4. Richard Grieve & John Cairns & Simon G. Thompson, 2010. "Improving costing methods in multicentre economic evaluation: the use of multiple imputation for unit costs," Health Economics, John Wiley & Sons, Ltd., vol. 19(8), pages 939-954, August.
    5. Manuel Gomes & Richard Grieve & Richard Nixon & Edmond S.‐W. Ng & James Carpenter & Simon G. Thompson, 2012. "Methods For Covariate Adjustment In Cost‐Effectiveness Analysis That Use Cluster Randomised Trials," Health Economics, John Wiley & Sons, Ltd., vol. 21(9), pages 1101-1118, September.
    6. Qi Cao & Erik Buskens & Hans L. Hillege & Tiny Jaarsma & Maarten Postma & Douwe Postmus, 2019. "Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(3), pages 475-482, April.
    7. Andrew H. Briggs, 2022. "Healing the past, reimagining the present, investing in the future: What should be the role of race as a proxy covariate in health economics informed health care policy?," Health Economics, John Wiley & Sons, Ltd., vol. 31(10), pages 2115-2119, October.
    8. Abualbishr Alshreef & Allan J. Wailoo & Steven R. Brown & James P. Tiernan & Angus J. M. Watson & Katie Biggs & Mike Bradburn & Daniel Hind, 2017. "Cost-Effectiveness of Haemorrhoidal Artery Ligation versus Rubber Band Ligation for the Treatment of Grade II–III Haemorrhoids: Analysis Using Evidence from the HubBLe Trial," PharmacoEconomics - Open, Springer, vol. 1(3), pages 175-184, September.
    9. Daisuke Goto & Ya-Chen Tina Shih & Pascal Lecomte & Melvin Olson & Chukwukadibia Udeze & Yujin Park & C. Daniel Mullins, 2017. "Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 35(7), pages 685-695, July.
    10. Carmen Selva-Sevilla & Elena Conde-Montero & Manuel Gerónimo-Pardo, 2020. "Bayesian Regression Model for a Cost-Utility and Cost-Effectiveness Analysis Comparing Punch Grafting Versus Usual Care for the Treatment of Chronic Wounds," IJERPH, MDPI, vol. 17(11), pages 1-21, May.
    11. DE RIDDER, Annemieke & DE GRAEVE, Diana, 2007. "Comparing the cost-effectiveness of Haloperidol, Risperidone and Olanzapine in the treatment of schizophrenia using the net-benefit regression approach," Working Papers 2007012, University of Antwerp, Faculty of Business and Economics.
    12. Jasjeet Singh Sekhon & Richard D. Grieve, 2012. "A matching method for improving covariate balance in cost‐effectiveness analyses," Health Economics, John Wiley & Sons, Ltd., vol. 21(6), pages 695-714, June.
    13. Janneke Grutters & Mark Sculpher & Andrew Briggs & Johan Severens & Math Candel & James Stahl & Dirk Ruysscher & Albert Boer & Bram Ramaekers & Manuela Joore, 2013. "Acknowledging Patient Heterogeneity in Economic Evaluation," PharmacoEconomics, Springer, vol. 31(2), pages 111-123, February.
    14. William Hollingworth & Christopher G. Fawsitt & Padraig Dixon & Larisa Duffy & Ricardo Araya & Tim J. Peters & Howard Thom & Nicky J. Welton & Nicola Wiles & Glyn Lewis, 2020. "Cost-Effectiveness of Sertraline in Primary Care According to Initial Severity and Duration of Depressive Symptoms: Findings from the PANDA RCT," PharmacoEconomics - Open, Springer, vol. 4(3), pages 427-438, September.
    15. Todd H. Wagner & Alex R. Dopp & Heather T. Gold, 2020. "Estimating Downstream Budget Impacts in Implementation Research," Medical Decision Making, , vol. 40(8), pages 968-977, November.
    16. Andrea Manca & Neil Hawkins & Mark J. Sculpher, 2005. "Estimating mean QALYs in trial‐based cost‐effectiveness analysis: the importance of controlling for baseline utility," Health Economics, John Wiley & Sons, Ltd., vol. 14(5), pages 487-496, May.
    17. Todd H. Wagner & Jean Yoon & Josephine C. Jacobs & Angela So & Amy M. Kilbourne & Wei Yu & David E. Goodrich, 2020. "Estimating Costs of an Implementation Intervention," Medical Decision Making, , vol. 40(8), pages 959-967, November.
    18. David Meads & Andrea Marshall & Claire Hulme & Janet Dunn & Hugo Ford, 2016. "The Cost Effectiveness of Docetaxel and Active Symptom Control versus Active Symptom Control Alone for Refractory Oesophagogastric Adenocarcinoma: Economic Analysis of the COUGAR-02 Trial," PharmacoEconomics, Springer, vol. 34(1), pages 33-42, January.
    19. A. Gafni & S. D. Walter & S. Birch & P. Sendi, 2008. "An opportunity cost approach to sample size calculation in cost‐effectiveness analysis," Health Economics, John Wiley & Sons, Ltd., vol. 17(1), pages 99-107, January.
    20. Richard Grieve & Richard Nixon & Simon G. Thompson & Charles Normand, 2005. "Using multilevel models for assessing the variability of multinational resource use and cost data," Health Economics, John Wiley & Sons, Ltd., vol. 14(2), pages 185-196, February.
    21. Gemma E. Shields & Mark Wilberforce & Paul Clarkson & Tracey Farragher & Arpana Verma & Linda M. Davies, 2022. "Factors Limiting Subgroup Analysis in Cost-Effectiveness Analysis and a Call for Transparency," PharmacoEconomics, Springer, vol. 40(2), pages 149-156, February.
    22. Manuel Gomes & Richard Grieve & Richard Nixon & W. J. Edmunds, 2012. "Statistical Methods for Cost-Effectiveness Analyses That Use Data from Cluster Randomized Trials," Medical Decision Making, , vol. 32(1), pages 209-220, January.
    23. Padraig Dixon & William Hollingworth & Jonathan Benger & James Calvert & Melanie Chalder & Anna King & Stephanie MacNeill & Katherine Morton & Emily Sanderson & Sarah Purdy, 2020. "Observational Cost-Effectiveness Analysis Using Routine Data: Admission and Discharge Care Bundles for Patients with Chronic Obstructive Pulmonary Disease," PharmacoEconomics - Open, Springer, vol. 4(4), pages 657-667, December.
    24. Nicholas Graves & Mary Courtney & Helen Edwards & Anne Chang & Anthony Parker & Kathleen Finlayson, 2009. "Cost-Effectiveness of an Intervention to Reduce Emergency Re-Admissions to Hospital among Older Patients," PLOS ONE, Public Library of Science, vol. 4(10), pages 1-9, October.
    25. Andrew Briggs, 2012. "Statistical Methods for Cost-effectiveness Analysis Alongside Clinical Trials," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 50, Edward Elgar Publishing.
    26. Mike Paulden, 2020. "Why it’s Time to Abandon the ICER," PharmacoEconomics, Springer, vol. 38(8), pages 781-784, August.
    27. Katia Noyes & Andrew W. Dick & Robert G. Holloway, 2004. "Pramipexole v. Levodopa as Initial Treatment for Parkinson’s Disease: A Randomized Clinical-Economic Trial," Medical Decision Making, , vol. 24(5), pages 472-485, October.
    28. John Hutton, 2012. "‘Health Economics’ and the evolution of economic evaluation of health technologies," Health Economics, John Wiley & Sons, Ltd., vol. 21(1), pages 13-18, January.
    29. Richard Grieve & Richard Nixon & Simon G. Thompson & John Cairns, 2007. "Multilevel models for estimating incremental net benefits in multinational studies," Health Economics, John Wiley & Sons, Ltd., vol. 16(8), pages 815-826, August.
    30. Andrew R. Willan & Andrew H. Briggs & Jeffrey S. Hoch, 2004. "Regression methods for covariate adjustment and subgroup analysis for non‐censored cost‐effectiveness data," Health Economics, John Wiley & Sons, Ltd., vol. 13(5), pages 461-475, May.
    31. Christian Brettschneider & Sebastian Kohlmann & Benjamin Gierk & Bernd Löwe & Hans-Helmut König, 2017. "Depression screening with patient-targeted feedback in cardiology: The cost-effectiveness of DEPSCREEN-INFO," PLOS ONE, Public Library of Science, vol. 12(8), pages 1-15, August.
    32. Mohamed El Alili & Johanna M. van Dongen & Jonas L. Esser & Martijn W. Heymans & Maurits W. van Tulder & Judith E. Bosmans, 2022. "A scoping review of statistical methods for trial‐based economic evaluations: The current state of play," Health Economics, John Wiley & Sons, Ltd., vol. 31(12), pages 2680-2699, December.
    33. Luigi Siciliani & James Gaughan & Nils Gutacker & Hugh Gravelle & Martin Chalkley, 2021. "Paying for health gains," Working Papers 183cherp, Centre for Health Economics, University of York.
    34. Quang Dang Nguyen & Mikhail Prokopenko, 2022. "A general framework for optimising cost-effectiveness of pandemic response under partial intervention measures," Papers 2205.08996, arXiv.org, revised Nov 2022.
    35. Miguel A. Negrín & Francisco J. Vázquez-Polo & María Martel & Elías Moreno & Francisco J. Girón, 2010. "Bayesian Variable Selection in Cost-Effectiveness Analysis," IJERPH, MDPI, vol. 7(4), pages 1-20, April.
    36. Kim Olsen & Lone Bilde & Henrik Juhl & Niels Kjaer & Holger Mosbech & Torben Evald & Mette Rasmussen & Helle Hiladakis, 2006. "Cost-effectiveness of the Danish smoking cessation interventions," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(4), pages 255-264, December.
    37. Victoria K. Brennan & Georgina Jones & Stephen Radley & Simon Dixon, 2021. "Incorporating Process Utility into Cost-Effectiveness Analysis via a Bolt-On Domain to the SF-6D: An Exploratory Study," Applied Health Economics and Health Policy, Springer, vol. 19(5), pages 747-756, September.
    38. Rissanen, Elisa & Karjalainen, Piia & Kiviruusu, Olli & Kankaanpää, Eila & Aronen, Eeva T. & Haula, Taru & Sääksvuori, Lauri & Vornanen, Riitta & Linnosmaa, Ismo, 2024. "Cost-effectiveness of a parenting program to reduce children’s behavioral problems among families receiving child protection services and other family support services – A randomized controlled trial," Children and Youth Services Review, Elsevier, vol. 158(C).
    39. Jones, A. & Lomas, J. & Rice, N., 2014. "Going Beyond the Mean in Healthcare Cost Regressions: a Comparison of Methods for Estimating the Full Conditional Distribution," Health, Econometrics and Data Group (HEDG) Working Papers 14/26, HEDG, c/o Department of Economics, University of York.
    40. Claudia Schulz & Gisela Büchele & Raphael S. Peter & Dietrich Rothenbacher & Christian Brettschneider & Ulrich C. Liener & Clemens Becker & Kilian Rapp & Hans-Helmut König, 2021. "Health-economic evaluation of collaborative orthogeriatric care for patients with a hip fracture in Germany: a retrospective cohort study using health and long-term care insurance claims data," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(6), pages 873-885, August.
    41. Andrea Manca & Paul C. Lambert & Mark Sculpher & Nigel Rice, 2007. "Cost-Effectiveness Analysis Using Data from Multinational Trials: The Use of Bivariate Hierarchical Modeling," Medical Decision Making, , vol. 27(4), pages 471-490, July.
    42. Ilias Goranitis & Joanna Coast & Ed Day & Alex Copello & Nick Freemantle & Emma Frew, 2017. "Maximizing Health or Sufficient Capability in Economic Evaluation? A Methodological Experiment of Treatment for Drug Addiction," Medical Decision Making, , vol. 37(5), pages 498-511, July.
    43. Negri­n, Miguel A. & Vázquez-Polo, Francisco-José, 2008. "Incorporating model uncertainty in cost-effectiveness analysis: A Bayesian model averaging approach," Journal of Health Economics, Elsevier, vol. 27(5), pages 1250-1259, September.
    44. Caffray, Christine M. & Chatterji, Pinka, 2009. "Developing an Internet-based survey to collect program cost data," Evaluation and Program Planning, Elsevier, vol. 32(1), pages 62-73, February.
    45. Wang, Limin, 2003. "Determinants of child mortality in LDCs: Empirical findings from demographic and health surveys," Health Policy, Elsevier, vol. 65(3), pages 277-299, September.
    46. Carl Bonander & Mikael Svensson, 2021. "Using causal forests to assess heterogeneity in cost‐effectiveness analysis," Health Economics, John Wiley & Sons, Ltd., vol. 30(8), pages 1818-1832, August.
    47. Theodoros Mantopoulos & Paul M. Mitchell & Nicky J. Welton & Richard McManus & Lazaros Andronis, 2016. "Choice of statistical model for cost-effectiveness analysis and covariate adjustment: empirical application of prominent models and assessment of their results," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(8), pages 927-938, November.
    48. Andrew M. Jones & James Lomas & Peter T. Moore & Nigel Rice, 2016. "A quasi-Monte-Carlo comparison of parametric and semiparametric regression methods for heavy-tailed and non-normal data: an application to healthcare costs," Journal of the Royal Statistical Society Series A, Royal Statistical Society, vol. 179(4), pages 951-974, October.
    49. Zou, Guang Yong & Taleban, Julia & Huo, Cindy Y., 2009. "Confidence interval estimation for lognormal data with application to health economics," Computational Statistics & Data Analysis, Elsevier, vol. 53(11), pages 3755-3764, September.
    50. Sennen Hounton & David Newlands, 2012. "Applying the Net-Benefit Framework for Analyzing and Presenting Cost-Effectiveness Analysis of a Maternal and Newborn Health Intervention," PLOS ONE, Public Library of Science, vol. 7(7), pages 1-8, July.
    51. Hormuzd A. Katki & Ionut Bebu, 2021. "A simple framework to identify optimal cost‐effective risk thresholds for a single screen: Comparison to Decision Curve Analysis," Journal of the Royal Statistical Society Series A, Royal Statistical Society, vol. 184(3), pages 887-903, July.
    52. Elamin H. Elbasha, 2005. "Risk aversion and uncertainty in cost‐effectiveness analysis: the expected‐utility, moment‐generating function approach," Health Economics, John Wiley & Sons, Ltd., vol. 14(5), pages 457-470, May.
    53. Yu-Wen Wen & Yi-Wen Tsai & David Bin-Chia Wu & Pei-Fen Chen, 2013. "The Impact of Outliers on Net-Benefit Regression Model in Cost-Effectiveness Analysis," PLOS ONE, Public Library of Science, vol. 8(6), pages 1-9, June.
    54. Anna M. Kashcheeva, 2019. "Assessment of the factors of mental health of the elderly population of Russia on the basis of individual data," Population and Economics, ARPHA Platform, vol. 3(3), pages 117-140, September.
    55. F. J. Vázquez‐Polo & M. A. Negrín Hernández & B. González López‐Valcárcel, 2005. "Using covariates to reduce uncertainty in the economic evaluation of clinical trial data," Health Economics, John Wiley & Sons, Ltd., vol. 14(6), pages 545-557, June.
    56. Wanrudee Isaranuwatchai & Maureen Markle-Reid & Jeffrey Hoch, 2015. "Adjusting for Baseline Covariates in Net Benefit Regression: How You Adjust Matters," PharmacoEconomics, Springer, vol. 33(10), pages 1083-1090, October.
    57. Peter Makai & Willemijn Looman & Eddy Adang & René Melis & Elly Stolk & Isabelle Fabbricotti, 2015. "Cost-effectiveness of integrated care in frail elderly using the ICECAP-O and EQ-5D: does choice of instrument matter?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(4), pages 437-450, May.
    58. Gomes, M & Grieve, R, 2011. "Estimating the Effects of Friendship Networks on Health Behaviors of Adolescents," Health, Econometrics and Data Group (HEDG) Working Papers 11/14, HEDG, c/o Department of Economics, University of York.
    59. Andrew M. Jones & James Lomas & Nigel Rice, 2015. "Healthcare Cost Regressions: Going Beyond the Mean to Estimate the Full Distribution," Health Economics, John Wiley & Sons, Ltd., vol. 24(9), pages 1192-1212, September.
    60. Yong-Jin Kim & Mark Oremus & Helen H. Chen & Thomas McFarlane & Danielle Fearon & Susan Horton, 2021. "Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada," PharmacoEconomics, Springer, vol. 39(5), pages 537-548, May.
    61. Gafni, Amiram & Birch, Stephen, 2006. "Incremental cost-effectiveness ratios (ICERs): The silence of the lambda," Social Science & Medicine, Elsevier, vol. 62(9), pages 2091-2100, May.
    62. Ya-Chen Shih & Nebiyou Bekele & Ying Xu, 2007. "Use of Bayesian Net Benefit Regression Model to Examine the Impact of Generic Drug Entry on the Cost Effectiveness of Selective Serotonin Reuptake Inhibitors in Elderly Depressed Patients," PharmacoEconomics, Springer, vol. 25(10), pages 843-862, October.
    63. Francisco-José Polo & Miguel Negrín & Xavier Badía & Montse Roset, 2005. "Bayesian regression models for cost-effectiveness analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(1), pages 45-52, March.
    64. Lynch, Frances L. & Dickerson, John F. & Saldana, Lisa & Fisher, Phillip A., 2014. "Incremental net benefit of early intervention for preschool-aged children with emotional and behavioral problems in foster care," Children and Youth Services Review, Elsevier, vol. 36(C), pages 213-219.
    65. Richard M. Nixon & David Wonderling & Richard D. Grieve, 2010. "Non‐parametric methods for cost‐effectiveness analysis: the central limit theorem and the bootstrap compared," Health Economics, John Wiley & Sons, Ltd., vol. 19(3), pages 316-333, March.
    66. Canaviri, Jose, 2007. "A Random Parameter Logit model for modeling Health Care Provider Choice in Bolivia," MPRA Paper 3263, University Library of Munich, Germany.
    67. Hoch, Jeffrey S. & Blume, Jeffrey D., 2008. "Measuring and illustrating statistical evidence in a cost-effectiveness analysis," Journal of Health Economics, Elsevier, vol. 27(2), pages 476-495, March.
    68. Lukasz Tanajewski & Matthew Franklin & Georgios Gkountouras & Vladislav Berdunov & Judi Edmans & Simon Conroy & Lucy E Bradshaw & John R F Gladman & Rachel A Elliott, 2015. "Cost-Effectiveness of a Specialist Geriatric Medical Intervention for Frail Older People Discharged from Acute Medical Units: Economic Evaluation in a Two-Centre Randomised Controlled Trial (AMIGOS)," PLOS ONE, Public Library of Science, vol. 10(5), pages 1-18, May.
    69. Jason R. Guertin & Blanchard Conombo & Raphaël Langevin & Frédéric Bergeron & Anne Holbrook & Brittany Humphries & Alexis Matteau & Brian J. Potter & Christel Renoux & Jean-Éric Tarride & Madelein, 2020. "A Systematic Review of Methods Used for Confounding Adjustment in Observational Economic Evaluations in Cardiology Conducted between 2013 and 2017," Medical Decision Making, , vol. 40(5), pages 582-595, July.
    70. Alexander Thompson & Bruce Guthrie & Katherine Payne, 2017. "Using the Payoff Time in Decision-Analytic Models: A Case Study for Using Statins in Primary Prevention," Medical Decision Making, , vol. 37(7), pages 759-769, October.
    71. Richard M. Nixon & Simon G. Thompson, 2005. "Methods for incorporating covariate adjustment, subgroup analysis and between‐centre differences into cost‐effectiveness evaluations," Health Economics, John Wiley & Sons, Ltd., vol. 14(12), pages 1217-1229, December.
    72. Hla-Hla Thein & Yao Qiao & Ahmad Zaheen & Nathaniel Jembere & Gonzalo Sapisochin & Kelvin K W Chan & Eric M Yoshida & Craig C Earle, 2017. "Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting," PLOS ONE, Public Library of Science, vol. 12(10), pages 1-20, October.
    73. David J. Vanness & John Mullahy, 2012. "Moving Beyond Mean-based Evaluation of Health Care," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 52, Edward Elgar Publishing.
    74. Mike Paulden, 2020. "Calculating and Interpreting ICERs and Net Benefit," PharmacoEconomics, Springer, vol. 38(8), pages 785-807, August.

Chapters

    Sorry, no citations of chapters recorded.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Co-authorship network on CollEc

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Jeffrey Hoch should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.